Denosumab is used in osteoporosis management in which context?

• A. A vitamin D analog.
• B. First-line for all patients regardless of risk.
• C. Used for high fracture risk or on steroids when antiresorptives are insufficient; acts on RANKL to inhibit osteoclasts.
• D. A calcium supplement.

Answer: (C)

Denosumab works by binding to RANKL, a molecule that signals osteoclast precursors to mature and become bone-resorbing cells. By blocking RANKL, denosumab prevents osteoclast formation and activity, which slows bone loss and lowers fracture risk.

In osteoporosis management, this makes denosumab a good option for people at high fracture risk or for those on long-term steroids when other antiresorptives aren’t sufficient or tolerated. It isn’t a vitamin D analog, nor is it a calcium supplement, and it isn’t used as the universal first-line therapy for everyone regardless of risk.

Practical notes: denosumab is given as a subcutaneous injection every six months. When stopping treatment, there can be a rebound increase in bone turnover, so plan a transition to another antiresorptive if stopping. Ensure adequate calcium and vitamin D and monitor for hypocalcemia, especially in patients with kidney problems.